TABLE 2.
Recombinant peptides used for antibody response and lymphocyte proliferation assays
| Subfamily and peptide | Amino acid sequence limits | Size (no. of residues) | Identitya with T. paraluiscuniculi predicted ORFs |
|---|---|---|---|
| Subfamily I | |||
| 5′-subfamily 1 | YAGVLT. . . . . QHQDPA | 267 | 98.6% identity with TprC and TprD before frameshift |
| TprF (N-terminal and central region) | YAGVLT. . . . . GTGGAC | 349 | 98.6% identity with TprC and TprD before frameshift |
| TprD2-central | TSLGD. . . . . WLQFTY | 90 | 96% with TprC and TprD |
| 3′-subfamily I (A)b | GFLRLE. . . . . TKSGDP | 86 | 81% with TprC and TprD |
| 3′-subfamily I (B)b | RIPGLS. . . . . IAESIW | 76 | 82% with TprC and TprD |
| TprI-central | RLTLEP. . . . . YTHLLT | 211 | 80% with TprG/I hybrid |
| Subfamily II | |||
| TprG-central | RLTLEP. . . . . DLIPKT | 219 | 85.3% with TprG1 and TprG2 |
| 3′-Subfamily II | LFTAQW. . . . . GVTLSV | 202 | 89.3% with TprG1; 89.6% with TprG2 |
| TprE-central | RLTLEP. . . . . QQTVAA | 191 | 9.5% with TprG1 and TprG2 |
| TprJ-central | RLTLEP. . . . . MRTEIT | 226 | 56.6% with TprG1 and TprG2 |
| Subfamily III | |||
| TprA (N-terminus) | MRLVLG. . . . . NCGTRR | 253 | 91.6% |
| TprA (C-terminus) | MGLVVT. . . . . GCKITW | 368 | 90% |
| TprB-central | RLTLSP. . . . . SLSKLV | 194 | 99.4% |
| TprH-central | RITLTP. . . . . YTHLID | 180 | 98.8% |
| TprK-centralc | IEGYAE. . . . . DTSFLE | 315 | 84% |
| TprLd | NA | NA | NA |
a
To define identity, T. pallidum recombinant peptide sequences were aligned with their T. paraluiscuniculi homologues and the value was calculated as (number of identical amino acids in identical position/recombinant peptide size) × 100.
b
3′-subfamily I A and B are partially overlapping peptides encompassing positions 313 to 395 (peptide A) and 379 to 454 (peptide B) of T. paraluiscuniculi TprC and TprD (B ORF, Fig. 1), respectively.
c
The TprK 1.1 clone was used for this calculation.
d
Recombinant peptide not available (NA).